ReviewFrontiers in immunology2015
Type II NKT Cells in Inflammation, Autoimmunity, Microbial Immunity, and Cancer.
Review in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 78 citations in OpenAlex.
- Cytokine-mediated, organ-specific immune modulation and dysregulation of innate lymphocytes in sepsis.Seminars in immunopathology · 2026Review
- Natural killer T cells in intracerebral hemorrhage: phase-dependent immune responses and therapeutic implications.Frontiers in immunology · 2026Review
- Potential biomarkers for predicting the efficacy of a pembrolizumab-containing regimen in advanced cervical cancer: A real-world analysis.Turkish journal of obstetrics and gynecology · 2025Article
- T cells in cancer: mechanistic insights and therapeutic advances.Biomarker research · 2025Review
- Can invariant Natural Killer T cells drive B cell fate? a look at the humoral response.Frontiers in immunology · 2025Review
- Potential mechanisms of natural metabolites and botanical drugs foumulae for the treatment of non-alcoholic fatty liver disease: targeting the gut microbiota to modulate the immune system.Frontiers in pharmacology · 2025Review
- Macrophages and Pulmonary Fibrosis.Current molecular medicine · 2025Review
- Optimizing iNKT-driven immune responses against cancer by modulating CD1d in tumor and antigen presenting cells.Clinical immunology (Orlando, Fla.) · 2024Review
- NKT cells promote Th1 immune bias to dengue virus that governs long-term protective antibody dynamics.The Journal of clinical investigation · 2024Article
- Natural Killer Cells and Cytotoxic T Cells: Complementary Partners against Microorganisms and Cancer.Microorganisms · 2024Review
- Antigen-specificity measurements are the key to understanding T cell responses.Frontiers in immunology · 2023Review
- The role of natural killer T cells in liver transplantation.Frontiers in cell and developmental biology · 2023Review
- Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis.Frontiers in immunology · 2023Review
- Prognostic and immunological role of sulfatide-related lncRNAs in hepatocellular carcinoma.Frontiers in oncology · 2023Article
- The repertoire of protein-sulfatide interactions reveal distinct modes of sulfatide recognition.Frontiers in molecular biosciences · 2022Review
- Serum sPD1 and sPDL1 as Biomarkers for Evaluating the Immune State of Lung Adenocarcinoma Patients.Journal of immunology research · 2022Article
- The Role of Type I and Type II NKT Cells in Materno-Fetal Immunity.Biomedicines · 2021Review
- The role of lymphocytes in neonatal encephalopathy.Brain, behavior, & immunity - health · 2021Review
- Does exercise attenuate age- and disease-associated dysfunction in unconventional T cells? Shining a light on overlooked cells in exercise immunology.European journal of applied physiology · 2021Review
- Type I Natural Killer T Cells as Key Regulators of the Immune Response to Infectious Diseases.Clinical microbiology reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Natural killer T cells (NKT) recognize self and microbial lipid antigens presented by non-polymorphic CD1d molecules. Two major NKT cell subsets, type I and II, express different types of antigen receptors (TCR) with distinct mode of CD1d/lipid recognition. Though type II NKT cells are less frequent in mice and difficult to study, they are predominant in human. One of the major subsets of type II NKT cells reactive to the self-glycolipid sulfatide is the best characterized and has been shown to induce a dominant immune regulatory mechanism that controls inflammation in autoimmunity and in anti-cancer immunity. Recently, type II NKT cells reactive to other self-glycolipids and phospholipids have been identified suggesting both promiscuous and specific TCR recognition in microbial immunity as well. Since the CD1d pathway is highly conserved, a detailed understanding of the biology and function of type II NKT cells as well as their interplay with type I NKT cells or other innate and adaptive T cells will have major implications for potential novel interventions in inflammatory and autoimmune diseases, microbial immunity, and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.